NCT05899621Recruiting
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
A Real-world Study of the Efficacy and Safety of Obinutuzumab-based Therapy for Previously Untreated Follicular Lymphoma
Source: ClinicalTrials.gov · Last updated 12 Jun 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 332 (estimated)
- First submitted
- 1 May 2023
- Start date
- 1 Jun 2023
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Ruijin Hospital
- Diseases
- Follicular lymphoma
- NCT number
- NCT05899621
What you commit to
- Study type: Observational
- Planned participants: 332
- From 1 Jun 2023 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any drug contraindication in the treatment plan
Other illness
- HBsAg positive and / or HBcAb positive with HBV DNA titer; HCV antibody positive with HCV-RNA; or HIV positive
Other
- Transformed follicular lymphoma or 3B follicular lymphoma;
- Central nervous system or meninges involved
- Patients judged by other researchers to be unsuitable for inclusion in the study
Who the study is looking for
- Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification
- Treatment naive
- Age ≥ 18 years
- Indications for treatment confirmed
- Must has measurable lesion in CT or PET-CT prior to treatment
- Considered suitable for GR, GB or GCHOP regimens
- Informed consented
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.